ERNA Stock Almost Doubled In Value Today – Smashing Rally Leads To 7 Trading Halts

• Loss per share narrowed to $6.95 from a loss of $57.76 per share last year.
• Last week, the firm said its therapy completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models.
• CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug application in the third quarter of 2026

Shares of Ernexa Therapeutics Inc. (ERNA) extended their explosive rally on Tuesday, soaring more than 90% as investors piled into the biotech stock following a sharp narrowing of first-quarter losses and growing optimism around its promising ovarian cancer cell therapy program.

Ernexa Therapeutics reported a first-quarter net loss of $5.51 million, narrower than the $8.20 million loss in the previous corresponding period. The company also posted a sharp improvement in loss per share, which narrowed to $6.95 from $57.76 a year earlier.

Trading in ERNA shares was halted seven times after the opening bell, according to NYSE data.

Retail Can’t Stop Talking About ERNA’s Ovarian Cancer Trial Results

Retail sentiment for ERNA shares on Stocktwits remained in the ‘extremely bullish’ territory, while message volumes increased by around 280% over a 24-hour period. ERNA was also among the top trending tickers on the platform.

One user said the stock is a “long-term” investment, citing the trial update.

Another user said they were ‘hyper bullish’ about the trial results, but would not rule out a stock offering.

ERNA To File NDA BY Q3

Last week, Ernexa said its ERNA-101 therapy, combined with PD-1 immunotherapy, completely cleared tumors and achieved 100% long-term survival in syngeneic ovarian cancer models, using mice. The therapy also boosted cancer-fighting immune activity and reduced tumor burden.

In a letter to shareholders on Monday, CEO Sanjeev Luther said the company remains on track to submit an Investigational New Drug (IND) application in the third quarter (Q3) of 2026 and plans to begin a Phase 1 human trial later in the year.

The stock has rallied nearly 250% since the pre-clinical trial results were reported.

The company implemented a 1-for-25 reverse stock split earlier this month.

Read also: RIGL Stock Jumps 15%, Short Interest Surges To Record High – Why Is Retail Eyeing A Further 40% Upside?

For updates and corrections, email newsroom[at]stocktwits[dot]com.